Dr. Kumar’s Take:
This is a narrative review, not a head-to-head trial. The authors compared oral minoxidil, finasteride, and dutasteride for androgenetic alopecia and synthesised the literature into a probable efficacy ranking, with 0.5 mg/day oral dutasteride at the top. A ranking of that kind reflects the authors’ judgement across a body of evidence, so I read the order as a considered synthesis rather than a measured league table. The mechanistic explanation for dutasteride’s position is straightforward: it blocks both isoenzymes that make DHT, while finasteride blocks only one.
Free guide: I put the complete, evidence-based plan into The Hair Loss Protocol, a downloadable guide you can take to your doctor.
Brief Summary:
The review covers oral minoxidil, finasteride, and dutasteride for male AGA. In decreasing order of probable efficacy, the authors place dutasteride 0.5 mg/day first, then finasteride 5 mg/day, then minoxidil 5 mg/day, then finasteride 1 mg/day, then minoxidil 0.25 mg/day. Oral finasteride at 1 mg/day is the FDA-approved option for male AGA. Oral minoxidil and oral dutasteride are not approved for it, though clinicians increasingly prescribe them off-label, and Japan and South Korea have approved oral dutasteride at 0.5 mg/day for male AGA.
Key Takeaways:
✔ Oral dutasteride (0.5 mg/day) sits at the top of the probable efficacy ranking.
✔ Oral finasteride (5 mg/day) ranks second, ahead of oral minoxidil (5 mg/day).
✔ Oral minoxidil 0.25 mg/day ranks last of the five options considered.
✔ The side effect profiles differ by drug class: minoxidil causes hypertrichosis and cardiovascular symptoms in a dose-dependent way, while finasteride and dutasteride are associated with sexual dysfunction and neuropsychiatric effects.
Study Design:
This is a review of the available evidence on oral minoxidil, finasteride, and dutasteride in androgenetic alopecia, published in the Journal of Dermatological Treatment in 2022. The authors synthesised that evidence into a probable efficacy ranking and reviewed the pharmacokinetics, pharmacodynamics, and safety profiles of the three drugs.
Results:
✔ The probable efficacy ranking, in decreasing order: dutasteride 0.5 mg/day, finasteride 5 mg/day, minoxidil 5 mg/day, finasteride 1 mg/day, minoxidil 0.25 mg/day.
✔ Oral minoxidil’s adverse effects are predominantly hypertrichosis and cardiovascular symptoms and signs, and they are dose-dependent.
✔ Oral finasteride and dutasteride are associated with sexual dysfunction and neuropsychiatric side effects.
✔ Average plasma half-lives: minoxidil about 4 hours, finasteride about 4.5 hours, dutasteride about 5 weeks.
✔ Dutasteride suppresses DHT more than finasteride does, in both serum and scalp.
Understanding the Treatments:
Dutasteride
Dutasteride inhibits both Type I and Type II 5-α reductase, while finasteride inhibits only Type II. That is why dutasteride suppresses DHT levels more than finasteride does, in serum and in the scalp. It is not FDA-approved for hair loss, but it is used off-label and has been approved at 0.5 mg/day for male AGA in Japan and South Korea. Its average plasma half-life is about 5 weeks, far longer than finasteride’s roughly 4.5 hours.
Finasteride
Finasteride is FDA-approved for male AGA at 1 mg/day. In this review’s ranking, the 5 mg/day dose sits higher than the 1 mg/day dose. Finasteride inhibits the Type II 5-α reductase isoenzyme, and it is associated with sexual dysfunction and neuropsychiatric side effects.
Minoxidil
Minoxidil acts through several pathways to promote hair growth: it is a vasodilator, an anti-inflammatory agent, a Wnt/β-catenin signaling inducer, and an antiandrogen. Its average plasma half-life is about 4 hours. The oral form causes hypertrichosis and cardiovascular symptoms and signs in a dose-dependent way, so the dose matters for tolerability as well as for effect.
Related Studies and Research
Pharmaceutical treatments play a central role in combating androgenetic alopecia. To explore additional treatment strategies, see:
- Androgenetic Alopecia Treatments: A Comprehensive Review , A complete breakdown of available treatment options.
- Low-Level Light Therapy: A Non-Pharmaceutical Approach , Investigating the potential synergy between light therapy and drug-based treatments.
- Microneedling for Hair Growth: Enhancing Drug Absorption , How microneedling can improve the efficacy of minoxidil and finasteride.
- Saw Palmetto for Hair Growth: Natural DHT Reduction , Analyzing whether saw palmetto can act as a natural alternative to DHT blockers.
Frequently Asked Questions:
Which hair loss treatment ranked highest?
In this review’s probable efficacy ranking, 0.5 mg/day of oral dutasteride comes first, followed by 5 mg/day of oral finasteride and then 5 mg/day of oral minoxidil.
Why is dutasteride ranked above finasteride?
Dutasteride inhibits both Type I and Type II 5-α reductase, while finasteride inhibits only Type II. Dutasteride therefore suppresses DHT more than finasteride does, in serum and in the scalp.
What are the risks of dutasteride and finasteride?
Both are associated with sexual dysfunction and neuropsychiatric side effects. Dutasteride has a much longer average plasma half-life, about 5 weeks versus about 4.5 hours for finasteride, so it clears from the body far more slowly.
What are the risks of oral minoxidil?
Oral minoxidil predominantly causes hypertrichosis and cardiovascular symptoms and signs, and it does so in a dose-dependent manner.
Should I take 5 mg of finasteride instead of 1 mg?
The 5 mg dose ranks above the 1 mg dose in this review, but 1 mg/day is the FDA-approved dose for male AGA. That decision belongs in a conversation with your physician, weighing the higher position in the ranking against the side effect profile of the drug class.
Conclusion:
When treating androgenetic alopecia, the choice among minoxidil, finasteride, and dutasteride should be personalized to the patient’s medical history and risk tolerance. The three drugs carry different adverse effect profiles: oral minoxidil brings hypertrichosis and cardiovascular effects that scale with dose, while the 5-α reductase inhibitors bring sexual dysfunction and neuropsychiatric effects. Dutasteride’s roughly 5 week half-life also means any problem it causes takes a long time to wash out, which is worth weighing before starting it.
I read this review as a map of the landscape rather than a verdict. It is a synthesis of existing evidence, not a trial, and the ranking should inform a discussion with your physician rather than settle it.
